Nicolás Quezada1, Gregorio Maturana2, María Jesús Irarrázaval2, Rodrigo Muñoz3, Sebastián Morales2, Pablo Achurra3, Cristóbal Azócar2, Fernando Crovari3. 1. Department of Digestive Surgery, Upper Gastrointestinal and Hernia surgery division, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 362 Diagonal Paraguay, 4th Floor - Office 410, Santiago, Región Metropolitana, Chile. nfquezada@gmail.com. 2. Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, Avda. Libertador Bernando O'Higgins 340, Santiago, Chile. 3. Department of Digestive Surgery, Upper Gastrointestinal and Hernia surgery division, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile, 362 Diagonal Paraguay, 4th Floor - Office 410, Santiago, Región Metropolitana, Chile.
Abstract
INTRODUCTION: Laparoscopic bariatric surgery (LBS) in liver end-stage organ disease has been proven to improve organ function and patients' symptoms. A series of LBS in patients with cirrhosis have shown good results in weight loss, but increased risk of complications. Current literature is based on clinical series. This paper aims to compare LBS (69% gastric bypass) between patients with cirrhosis and without cirrhosis. METHODS: We conducted a retrospective 1:3 matched case-control study including bariatric patients with cirrhosis and without cirrhosis. Demographics, operative variables, postoperative complications, long-term weight loss, and comorbidity resolution were compared between groups. RESULTS: Sixteen Child A patients were included in the patients with cirrhosis (PC) group and 48 in patients without cirrhosis (control) group. Mean age was 50 years; preoperative BMI was 39 ± 6.8 kg/m2. Laparoscopic gastric bypass and laparoscopic sleeve gastrectomy were performed in 69% and 31%, respectively. Follow-up was 81% at 2 years for both groups. PC group had a higher rate of overall (31% vs. 6%; p < 0.05) and severe (Clavien-Dindo ≥ III; 13% vs. 0%; p = 0.013) complications than that of the control group. Mean %EWL of PC at 2 years of follow-up was 84.9%, without differences compared with that of the control group (83.1%). Comorbidity remission in PC was 14%, 50%, and 85% for hypertension, type 2 diabetes, and dyslipidemia, respectively. Patients without cirrhosis had a higher resolution rate of hypertension (65% vs. 14%, p = 0.03). CONCLUSION: LBS is effective for weight loss and comorbidity resolution in patients with obesity and Child A liver cirrhosis. However, these results are accompanied by significantly increased risk of complications.
INTRODUCTION: Laparoscopic bariatric surgery (LBS) in liver end-stage organ disease has been proven to improve organ function and patients' symptoms. A series of LBS in patients with cirrhosis have shown good results in weight loss, but increased risk of complications. Current literature is based on clinical series. This paper aims to compare LBS (69% gastric bypass) between patients with cirrhosis and without cirrhosis. METHODS: We conducted a retrospective 1:3 matched case-control study including bariatric patients with cirrhosis and without cirrhosis. Demographics, operative variables, postoperative complications, long-term weight loss, and comorbidity resolution were compared between groups. RESULTS: Sixteen Child A patients were included in the patients with cirrhosis (PC) group and 48 in patients without cirrhosis (control) group. Mean age was 50 years; preoperative BMI was 39 ± 6.8 kg/m2. Laparoscopic gastric bypass and laparoscopic sleeve gastrectomy were performed in 69% and 31%, respectively. Follow-up was 81% at 2 years for both groups. PC group had a higher rate of overall (31% vs. 6%; p < 0.05) and severe (Clavien-Dindo ≥ III; 13% vs. 0%; p = 0.013) complications than that of the control group. Mean %EWL of PC at 2 years of follow-up was 84.9%, without differences compared with that of the control group (83.1%). Comorbidity remission in PC was 14%, 50%, and 85% for hypertension, type 2 diabetes, and dyslipidemia, respectively. Patients without cirrhosis had a higher resolution rate of hypertension (65% vs. 14%, p = 0.03). CONCLUSION: LBS is effective for weight loss and comorbidity resolution in patients with obesity and ChildA liver cirrhosis. However, these results are accompanied by significantly increased risk of complications.
Authors: Annalisa Berzigotti; Guadalupe Garcia-Tsao; Jaime Bosch; Norman D Grace; Andrew K Burroughs; Rosa Morillas; Angels Escorsell; Juan Carlos Garcia-Pagan; David Patch; Daniel S Matloff; Roberto J Groszmann Journal: Hepatology Date: 2011-06-26 Impact factor: 17.425
Authors: David P Fisher; Eric Johnson; Sebastien Haneuse; David Arterburn; Karen J Coleman; Patrick J O'Connor; Rebecca O'Brien; Andy Bogart; Mary Kay Theis; Jane Anau; Emily B Schroeder; Stephen Sidney Journal: JAMA Date: 2018-10-16 Impact factor: 56.272
Authors: Ted D Adams; Lance E Davidson; Sheldon E Litwin; Jaewhan Kim; Ronette L Kolotkin; M Nazeem Nanjee; Jonathan M Gutierrez; Sara J Frogley; Anna R Ibele; Eliot A Brinton; Paul N Hopkins; Rodrick McKinlay; Steven C Simper; Steven C Hunt Journal: N Engl J Med Date: 2017-09-21 Impact factor: 91.245
Authors: Choon-Pin Lim; Oliver M Fisher; Dan Falkenback; Damien Boyd; Christopher S Hayward; Anne Keogh; Katherine Samaras; Peter MacDonald; Reginald V Lord Journal: Obes Surg Date: 2016-03 Impact factor: 4.129
Authors: Nicolas V Christou; John S Sampalis; Moishe Liberman; Didier Look; Stephane Auger; Alexander P H McLean; Lloyd D MacLean Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Lena M S Carlsson; Markku Peltonen; Sofie Ahlin; Åsa Anveden; Claude Bouchard; Björn Carlsson; Peter Jacobson; Hans Lönroth; Cristina Maglio; Ingmar Näslund; Carlo Pirazzi; Stefano Romeo; Kajsa Sjöholm; Elisabeth Sjöström; Hans Wedel; Per-Arne Svensson; Lars Sjöström Journal: N Engl J Med Date: 2012-08-23 Impact factor: 91.245
Authors: Rebecca O'Brien; Eric Johnson; Sebastien Haneuse; Karen J Coleman; Patrick J O'Connor; David P Fisher; Stephen Sidney; Andy Bogart; Mary Kay Theis; Jane Anau; Emily B Schroeder; David Arterburn Journal: Ann Intern Med Date: 2018-08-07 Impact factor: 25.391
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; Sofie Ahlin; Johanna Andersson-Assarsson; Åsa Anveden; Claude Bouchard; Björn Carlsson; Kristjan Karason; Hans Lönroth; Ingmar Näslund; Elisabeth Sjöström; Magdalena Taube; Hans Wedel; Per-Arne Svensson; Kajsa Sjöholm; Lena M S Carlsson Journal: JAMA Date: 2014-06-11 Impact factor: 56.272
Authors: Lars Sjöström; Kristina Narbro; C David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Ted Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Göran Agren; Lena M S Carlsson Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: Helena Castañé; Gerard Baiges-Gaya; Anna Hernández-Aguilera; Elisabet Rodríguez-Tomàs; Salvador Fernández-Arroyo; Pol Herrero; Antoni Delpino-Rius; Nuria Canela; Javier A Menendez; Jordi Camps; Jorge Joven Journal: Biomolecules Date: 2021-03-22